Cargando…
Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019
BACKGROUND: First-line immune checkpoint inhibitor (ICI) monotherapy for advanced non–small cell lung cancer (NSCLC) was introduced in Japan in February 2017. Limited information is available since that time regarding health care resource use for NSCLC in Japan, where the hospitalization burden is h...
Autores principales: | Goto, Yasushi, Kawamura, Kodai, Fukuhara, Tatsuro, Namba, Yukiko, Aoe, Keisuke, Shukuya, Takehito, Tsuda, Takeshi, Santorelli, Melissa L., Taniguchi, Kazuko, Kamitani, Tetsu, Irisawa, Masato, Kanda, Kingo, Abe, Machiko, Burke, Thomas, Nokihara, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372154/ https://www.ncbi.nlm.nih.gov/pubmed/37519418 http://dx.doi.org/10.1016/j.curtheres.2023.100712 |
Ejemplares similares
-
First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
por: Goto, Yasushi, et al.
Publicado: (2022) -
Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan
por: Nokihara, Hiroshi, et al.
Publicado: (2022) -
Real‐world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2023) -
Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2022) -
Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies
por: Tanaka, Midori, et al.
Publicado: (2018)